Cargando…

Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism

BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial h...

Descripción completa

Detalles Bibliográficos
Autores principales: Naito, Akira, Tanabe, Nobuhiro, Jujo, Takayuki, Shigeta, Ayako, Sugiura, Toshihiko, Sakao, Seiichiro, Ishida, Keiichi, Tatsumi, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239022/
https://www.ncbi.nlm.nih.gov/pubmed/25412085
http://dx.doi.org/10.1371/journal.pone.0113086
_version_ 1782345546877370368
author Naito, Akira
Tanabe, Nobuhiro
Jujo, Takayuki
Shigeta, Ayako
Sugiura, Toshihiko
Sakao, Seiichiro
Ishida, Keiichi
Tatsumi, Koichiro
author_facet Naito, Akira
Tanabe, Nobuhiro
Jujo, Takayuki
Shigeta, Ayako
Sugiura, Toshihiko
Sakao, Seiichiro
Ishida, Keiichi
Tatsumi, Koichiro
author_sort Naito, Akira
collection PubMed
description BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers. METHODS: Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers. RESULTS: The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients. CONCLUSIONS: Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis.
format Online
Article
Text
id pubmed-4239022
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-42390222014-11-26 Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism Naito, Akira Tanabe, Nobuhiro Jujo, Takayuki Shigeta, Ayako Sugiura, Toshihiko Sakao, Seiichiro Ishida, Keiichi Tatsumi, Koichiro PLoS One Research Article BACKGROUND: Pentraxin3 (PTX3) is a protein, which has multifaceted effects on innate immunity, angiogenesis, and vascular remodeling then could be a disease marker of acute myocardial infarction, heart failure, vasculitis. In addition, PTX3 has been recognized as a biomarker for pulmonary arterial hypertension, however whether it is the case in chronic thromboembolic pulmonary hypertension (CTEPH) remains unclear. Therefore, we investigated whether PTX3 would be a useful biomarker for detecting CTEPH with respect to differentiation from stable pulmonary thromboembolism (PTE), in comparison to other biomarkers. METHODS: Plasma PTX3 and brain natriuretic peptide (BNP) levels were measured in 70 patients with CTEPH at their first diagnostic right heart catheterization (CTEPH group) and in 20 patients with clinically stable PTE more than three months after the acute episode (control group). The levels of plasma C-reactive protein (CRP) and heart-type fatty acid-binding protein (H-FABP) were also analyzed to compare the diagnostic ability of these biomarkers. RESULTS: The mean level of PTX3 (ng/mL) was significantly higher in the CTEPH group than in the control group (5.51±4.53 versus 2.01±0.96, respectively), and PTX3 levels had mild negative correlation with cardiac output. BNP levels were also higher in the CTEPH group and better correlated with pulmonary hemodynamics than PTX3. However, a receiver operating characteristic (ROC) curve showed PTX3 levels were better for detecting CTEPH, and could detect CTEPH patients with less severe pulmonary hemodynamics and low plasma BNP levels. There was no significant increase in CRP and H-FABP levels in the CTEPH patients. CONCLUSIONS: Plasma PTX3 level was the most sensitive biomarker of CTEPH. Although plasma PTX3 levels did not correlate with the severity of the pulmonary hemodynamics compared to BNP, high levels in clinically stable patients following PTE should prompt a further work-up for CTEPH, which may lead to an early diagnosis. Public Library of Science 2014-11-20 /pmc/articles/PMC4239022/ /pubmed/25412085 http://dx.doi.org/10.1371/journal.pone.0113086 Text en © 2014 Naito et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Naito, Akira
Tanabe, Nobuhiro
Jujo, Takayuki
Shigeta, Ayako
Sugiura, Toshihiko
Sakao, Seiichiro
Ishida, Keiichi
Tatsumi, Koichiro
Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title_full Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title_fullStr Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title_full_unstemmed Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title_short Pentraxin3 in Chronic Thromboembolic Pulmonary Hypertension: A New Biomarker for Screening from Remitted Pulmonary Thromboembolism
title_sort pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4239022/
https://www.ncbi.nlm.nih.gov/pubmed/25412085
http://dx.doi.org/10.1371/journal.pone.0113086
work_keys_str_mv AT naitoakira pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT tanabenobuhiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT jujotakayuki pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT shigetaayako pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT sugiuratoshihiko pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT sakaoseiichiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT ishidakeiichi pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism
AT tatsumikoichiro pentraxin3inchronicthromboembolicpulmonaryhypertensionanewbiomarkerforscreeningfromremittedpulmonarythromboembolism